Reviewing Spectral Medical (OTCMKTS:EDTXF) and Biotricity (NASDAQ:BTCY)

Spectral Medical (OTCMKTS:EDTXFGet Free Report) and Biotricity (NASDAQ:BTCYGet Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership.

Insider & Institutional Ownership

32.5% of Biotricity shares are owned by institutional investors. 1.5% of Spectral Medical shares are owned by company insiders. Comparatively, 20.5% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Spectral Medical and Biotricity, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spectral Medical 0 0 0 0 N/A
Biotricity 0 1 0 0 2.00

Profitability

This table compares Spectral Medical and Biotricity’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spectral Medical -649.73% N/A -111.41%
Biotricity -146.61% N/A -249.45%

Earnings and Valuation

This table compares Spectral Medical and Biotricity’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spectral Medical $1.28 million 102.25 -$8.65 million ($0.03) -15.66
Biotricity $11.11 million 0.62 -$18.66 million ($1.59) -0.50

Spectral Medical has higher earnings, but lower revenue than Biotricity. Spectral Medical is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Spectral Medical has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Summary

Biotricity beats Spectral Medical on 6 of the 10 factors compared between the two stocks.

About Spectral Medical

(Get Free Report)

Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

About Biotricity

(Get Free Report)

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Receive News & Ratings for Spectral Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical and related companies with MarketBeat.com's FREE daily email newsletter.